Siren Biotechnology and Catalent Inc. entered a strategic partnership to support the development and manufacturing of Siren Biotechnology's AAV immuno-gene therapies. Under the partnership, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology's adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials. Catalent will further support process optimization at its process and clinical development center in Baltimore, MD.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.37 USD | +0.22% | -0.79% | +23.24% |
May. 16 | Argus Downgrades Catalent to Sell From Buy | MT |
May. 14 | Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.24% | 10.02B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer